Novo Nordisk Inks $2.1B Obesity Drug Deal

- The deal focuses on overcoming a major challenge in drug delivery: making biologic drugs, like proteins and peptides, effective when taken orally. These large molecules are typically broken down by the digestive system, which is why they have historically required administration by injection. - Vivtex, a startup co-founded by renowned MIT biomedical engineer Robert Langer, tackles this problem using a platform that combines high-throughput screening, computational simulation, and AI analytics to find ways to get these drugs absorbed by the gut. - The $2.1 billion figure represents the total potential value of the deal, which includes smaller upfront payments, research funding, and a series of "milestone" payments that Vivtex will receive only if the developed drugs succeed in clinical trials and get approved. - This partnership aims to build on Novo Nordisk's existing oral drug portfolio, which includes Rybelsus for diabetes and a pill form of the popular weight-loss drug Wegovy that was approved in late 2025. - The push for effective oral alternatives is driven by intense competition, primarily from Eli Lilly, and the massive market for GLP-1 drugs, which is projected to reach $150 billion globally by 2030. - Once the initial research and formulation phases are complete under the partnership, Novo Nordisk will take over the responsibilities of global development, managing regulatory approvals, manufacturing, and commercialization of any new drugs.